



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/617,025	07/11/2003	Makoto Komatsu	2003-0950A	2714
513	7590	01/25/2005	EXAMINER	
WENDEROTH, LIND & PONACK, L.L.P.			ASINOVSKY, OLGA	
2033 K STREET N. W.			ART UNIT	PAPER NUMBER
SUITE 800			1711	
WASHINGTON, DC 20006-1021				

DATE MAILED: 01/25/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)	
	10/617,025	KOMATSU ET AL.	
	Examiner	Art Unit	
	Olga Asinovsky	1711	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on 17 December 2004.

2a) This action is FINAL. 2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 1-33 is/are pending in the application.
4a) Of the above claim(s) 8-11 and 22-33 is/are withdrawn from consideration.

5) Claim(s) _____ is/are allowed.

6) Claim(s) 1-7 and 12-21 is/are rejected.

7) Claim(s) _____ is/are objected to.

8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on 11 July 2003 is/are: a) accepted or b) objected to by the Examiner.

 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) All b) Some * c) None of:
1. Certified copies of the priority documents have been received.
2. Certified copies of the priority documents have been received in Application No. _____.
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) Notice of References Cited (PTO-892)
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date Oct. 10 & Dec24, 2003

4) Interview Summary (PTO-413)
Paper No(s)/Mail Date. ____ .

5) Notice of Informal Patent Application (PTO-152)

6) Other: ____ .

DETAILED ACTION

Election/Restrictions

1. This application contains claims 8-11 and 22-33 drawn to an invention nonelected with traverse in Paper No. filed on Dec. 17, 2004. A complete reply to the final rejection must include cancellation of nonelected claims or other appropriate action (37 CFR 1.144) See MPEP § 821.01.

Claims 1-7 and 12-21 are under examination.

Claim Rejections - 35 USC § 102

2. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

3. Claims 1-7 and 12-21 are rejected under 35 U.S.C. 102(b) as being anticipated by Garnett et al U.S. Patent 3,880,736 or JP 7041574 (cited by applicants), or Frey et al U.S. Patent 5,863,654, or Sugo et al U.S. Patent 5,648,400.

Garnett discloses backbone polymer and graft polymerization of vinyl pyridine monomer via radiation induced graft polymerization. The backbone polymer can be polyethylene or polypropylene. The grafted vinyl pyridine monomer can have functional group such as amino, halogen nitro moiety, column 2, lines 15-27. The polymerized

polyvinylpyridine having functional group is readable in applicants' claimed polymer side chain having reactive functional group. The applicants' claims lack novelty.

JP 7041574 discloses a backbone polymer such as a porous polyethylene membrane or ethylene-tetrafluoroethylene copolymer grafted with chloromethylstyrene and introducing quaternary amine moiety into said graft-polymerized membrane. The graft polymerization is produced via irradiating a porous membrane, abstract.

Frey discloses porous hollow fiber made of a polyolefin material that is grafted with polyvinylidene chloride and in further coated with a biocompatible carbon material, column 3, lines 32-35 and 57-65, column 4, lines 19-57, column 8, lines 40-43 and column 20, lines 40-57. The graft polymerization is produced via radiation induced graft polymerization, column 6, lines 36-45, 55-65, column 13, line 60. The content of functional=reactive hydrogen chloride and a residue of (HCl) is controlled in the amount sufficient of being converted into a coating of a biocompatible carbon material, column 9, lines 19-20, 33-47.

Sugo discloses a process for producing polymeric electrolyte complex and ion--exchange resin. A polymeric substrate is grafted with polymerizable hydrophilic monomer through radiation-initiated graft polymerization, column 4, lines 5-60. The obtained ion-exchange resin is a solid reagent.

Double Patenting

4. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

5. Claims 1-7 and 12-22 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-5 of U.S. Patent No. 6,703,432. Although the conflicting claims are not identical, they are not patentably distinct from each other because the chemical formulation of a grafted polymer having a polymer side chain having functional group in claims 1-5 of Patent 6,703,432 is readable in applicants' claims. It would have been obvious to one of ordinary skill in the art to consider that the desiccant material in claims 1-5 of Patent 6,703,432 is reactive solid reagent because the polymer side chain have a cation exchange group selected from sulfonate acid group, phosphate group and carboxyl group.

6. A rejection based on double patenting of the "same invention" type finds its support in the language of 35 U.S.C. 101 which states that "whoever invents or discovers any new and useful process ... may obtain a patent therefor ..." (Emphasis added). Thus, the term "same invention," in this context, means an invention drawn to identical subject matter. See *Miller v. Eagle Mfg. Co.*, 151 U.S. 186 (1894); *In re*

Ockert, 245 F.2d 467, 114 USPQ 330 (CCPA 1957); and *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970).

A statutory type (35 U.S.C. 101) double patenting rejection can be overcome by canceling or amending the conflicting claims so they are no longer coextensive in scope. The filing of a terminal disclaimer cannot overcome a double patenting rejection based upon 35 U.S.C. 101.

7. Claims 1-7 and 12-22 are rejected under 35 U.S.C. 101 as claiming the same invention as that of claims 1-25 of prior U.S. Patent No. 6,811,771. This is a double patenting rejection. Claims 1-25 of Patent 6,811,771 discloses a reactive antimicrobial filter comprising organic polymer grafted with polymerized N-alkyl-N-vinylalkylamide monomer and introducing triiodide ion on the resulting polymer material. Claims 1-25 discloses the applicants' claimed solid reagent and a process for preparing said solid reagent.

Conclusion

8. The prior art made of record and not relied upon is considered pertinent to applicant's disclosure.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Olga Asinovsky whose telephone number is 571-272-1066. The examiner can normally be reached on 9:00 to 5:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James Seidleck can be reached on 571-272-1078. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Olga Asinovsky
Examiner
Art Unit 1711

O.A
January 21, 2005



James J. Seidleck
Supervisory Patent Examiner
Technology Center 1700